A Partnership Revolutionizing Dating, Courtesy of FROME X Hyde
If You’re a Man Living in NYC This Summer, Having Nothing to Wear is No Longer an Excuse
FROME x HYDE
Ask someone on a date, schedule a styling appointment, and the rest is taken care of by the HYDE Team.
NEW YORK, July 18, 2023 (Newswire.com)
–
First Round’s On Me, a dating app that is drastically changing how users approach dating by encouraging in-person connections, and Hyde, a menswear styling and rental clothing service, are thrilled to announce a new collaboration that makes finding dates, and looking your best for those dates, easier than ever before.
This partnership brings together two brands that are committed to changing the dating and fashion industry, through innovation, style, and client satisfaction. The FROME x Hyde integration makes it seamless to match with a date, book a styling appointment, and get a complete outfit and a curated look, delivered straight to your door, just in time for the date.
“First impressions matter, especially on a date. Our partnership with FROME means that the app’s users can get affordable, easy access to high-end designer clothing so they can look their best and feel their most confident,” says Hyde’s co-founder and Chief Product Officer Aaron Crist.
The FROME x Hyde integration is initially being rolled out to FROME’s male user base in the New York area, with the eventual goal of rolling out to all cities and genders. Sign up, get matched, and get started making real connections and looking your best — it’s never been easier.
For media inquiries or further information, please contact:
Public Relations and Media Managers
Marie Gloss
HYDE
[email protected]
Olivia Bradshaw
FROME
[email protected]
Contact Information:
Marie Gloss
Media & Strategy Manager
5716120847
Original Source:
A Partnership Revolutionizing Dating, Courtesy of FROME X Hyde
The post A Partnership Revolutionizing Dating, Courtesy of FROME X Hyde first appeared on RSVTV news.
FemAid Addresses Female Incontinence
FemAid Device Offers Relief from Female Incontinence
FemAid Test Stand View of FemAid pressure testing stand.
LOS…
Aperture Pet & Life Launches BRS Fresh Online Shopping Experience Tailored to Discerning Freshwater Aquarists
Launch Solidifies Bulk Reef Supply / BRS as the ultimate online shopping destination for both freshwater and saltwater aquarists.
…
The post Aperture Pet & Life Launches BRS Fresh Online Shopping Experience Tailored to Discerning Freshwater Aquarists first appeared on RSVTV news.
M2 Information Systems Launches Revolutionary IRIS Family Messaging: Reinventing Communication in Healthcare Settings
A Leader in Developing Cutting-Edge Hospital Applications, M2 Information Systems Launches IRIS Family Messaging to Help Streamline Communication & Foster Stronger Connections Between Patients, Their Families & Healthc…
Radiology Patient Action Network Urges Congress and CMS to Prevent ‘Cruel’ Cuts to Medicare Access
“With nearly half of Medicare-eligible women having gone years without receiving a mammogram,” noted Bob Still, the Executive Director of RBMA, “it is unconscionable for Congress to again decrease Medicare reimbursement for providers.”
FAIRFAX, Va., July 17, 2023 (Newswire.com)
–
The Radiology Business Management Association’s Radiology Patient Action Network (RPAN) urges Congress and the U.S. Center for Medicare and Medicaid Services (CMS) to safeguard Medicare funding for physicians in light of proposed cuts in payments to providers under the proposed 2024 Medicare Physician Fee Schedule (MPFS).
“With nearly half of Medicare-eligible women having gone years without receiving a mammogram, it is unconscionable for Congress to again decrease Medicare reimbursement for providers, particularly those who perform screenings and procedures that aid in detecting and treating life-threatening diseases,” said Bob Still, the Executive Director of RBMA. “These cruel cuts not only hinder access to healthcare for Medicare recipients, but they could harm Medicaid patients too since many states link Medicaid to Medicare rates. The continued cycle of reimbursement cuts will further reduce access, worsen health disparities, and cost the country an incalculable amount of money over the long term. Congress must take action to halt these substantial cuts to independent Medicare doctors and their patients.”
RPAN strongly urges Congress to pass H.R. 2474 on behalf of healthcare providers and patients nationwide. This legislation marks the beginning of a comprehensive reform to Medicare, including an adjustment for inflationary factors. These reforms mirror recommendations from MedPAC and other groups.
“While independent providers with high Medicare volumes face significant reductions in reimbursement, other provider types continue receiving inflationary updates and reimbursement increases,” explained Still. “This growing disparity in reimbursement will only foster more consolidation among healthcare providers, aggravating inequities between provider types, and ultimately limiting patient access to care.”
Contact Information:
Will Sweet
RBMA
Original Source:
Radiology Patient Action Network Urges Congress and CMS to Prevent ‘Cruel’ Cuts to Medicare Access
Remote Monitoring and Teledentistry App In Hand Dental Partners With Five Star Orthodontic Laboratory & Supply, Inc.
Five Star Orthodontic Laboratory & Supply, Inc. has been servicing the Orthodontic community for over 30 years. They will be using the In Hand Dental platform to add strategic value to their Tri-Aligners product line a…
Transform the Little Voice Inside Into a Powerful Roar: Dr. Esther Zeledón’s ‘Creating Your Limitless Life’ to Be Released on September 15, 2023
\”Creating Your Limitless Life\” Dr Esther Zeledon
\”Creating Your Limitless Life\” by Dr Esther Zeledon
MIAMI, July 17, 2023 (Newswire.com)
–
After migrating to the United States from Nicaragua as a young child, Esther Zeledón was destined to chase the American Dream. As a high achiever from an immigrant neighborhood, she ticked off each of the boxes on her checklist; graduated top of her class, received a scholarship to a prestigious college, completed a Ph.D. from UC Berkeley, had a career as a diplomat, and started a family. Everything suggested that her struggles had paid off and she had made it. Yet, she knew something was missing- alignment.
That was when she became limitless.
Find out how Dr Esther Zeledón went from burn-out to embracing the boundless life she now leads when Dean Publishing releases “Creating Your Limitless Life” this Hispanic Heritage Month on September 15, 2023 (9/15/23). Designed with the high achiever in mind, this inspiring book is a guide to awakening the extraordinary possibilities that await inside everybody no matter who they are or where they come from. With Esther’s incredible story and her three-step approach, “Creating Your Limitless Life” is a roadmap to living an authentic life full of joy.
“I wrote this book because I’ve seen so many people, myself included, get trapped in these societal molds that crush our spirits and leave us feeling anxious, depressed, and without clarity about who we are or what we want,” says Esther. “Even worse, we perpetuate the cycle by passing those same pressures on to others. We don’t stop to listen to what others really want or need, causing us to question ourselves and place our purpose and true legacy on the back burner. My life’s purpose is to unlock the full potential of individuals as they uncover, pursue, and financially support their missions, visions, and purposes. I want them to embrace their inner voice rather than fear it.”
Synopsis
“Creating Your Limitless Life” presents a transformative three-step approach, empowering high achievers to transcend societal expectations and navigate the challenges of balancing ambition with personal fulfillment. Drawing from Dr. Esther Zeledón’s experiences as an immigrant, entrepreneur, and diplomat, this book challenges conventional norms, highlighting the significance of active self-listening. Through practical tools and real-life case studies, readers are guided to listen and not fear their inner voice so they can uncover their purpose, craft a personalized roadmap, and cultivate resilience. Going beyond traditional self-help, this book equips individuals with the necessary resources to achieve clarity on their next steps, unlock their boundless potential and embrace a truly fulfilling life.
To pre-order “Creating Your Limitless Life” visit https://beactchange.com/creating-your-limitless-life-book
For media inquiries or to schedule an interview with Esther Zeledon, please contact enquiries @pricelessmedia.com.au
Contact Information:
Nicki Price
Managing Director/Publicist
Original Source:
Transform the Little Voice Inside Into a Powerful Roar: Dr. Esther Zeledón’s ‘Creating Your Limitless Life’ to Be Released on September 15, 2023
The post Transform the Little Voice Inside Into a Powerful Roar: Dr. Esther Zeledón’s ‘Creating Your Limitless Life’ to Be Released on September 15, 2023 first appeared on RSVTV news.
VALO Holdings Group and CEO Jana Seaman Empower Habitat for Humanity Collier County Florida Through Team Volunteer Efforts
VALO Holdings Group, led by CEO Jana Seaman, bring their team to sponsor and participate in a community event with Habitat for Humanity of Collier County — working on a new construction to benefit families in need.
…
The post VALO Holdings Group and CEO Jana Seaman Empower Habitat for Humanity Collier County Florida Through Team Volunteer Efforts first appeared on RSVTV news.
GOBEL Receives Second Patent for Gratitude to Give
ST. PETERSBURG, Fla., July 14, 2023 (Newswire.com)
–
GOBEL, the world’s leading consulting and technology firm working exclusively for healthcare philanthropy…
POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial
EuCorVac-19
EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes
BUFFALO, N.Y., July 14, 2023 (Newswire.com)
–
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO’s spontaneous-nanoliposome antigen particle (SNAP) technology.
The phase 3 trial of EuCorVac-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-19 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial.
The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac-19 compared to the control vaccine. EuCorVac-19 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. In immunogenicity analysis against the Omicron BA.5 strain, EuCorVac-19 induced more than twice the neutralizing antibody titer compared to the control vaccine.
EuCorVac-19’s safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events.
These results further validate the strength and synergy of POP BIO’s SNAP and EuBiologics’ EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future.
“Achieving the completion of this Phase III trial is an enormous milestone for our technologies. These results provide validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide,” said POP BIO co-founder Jonathan Smyth.
EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea.
Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.
About POP Biotechnologies: POP Biotechnologies, Inc. is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from the State University of New York Research Foundation (SUNY-RF), was developed by company co-founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo). POP Biotechnologies is currently a resident of the SUNY Buffalo incubator at Baird Research Park.
About POP BIO’s SNAP Technology: POP BIO’s Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious disease and cancer through the use of a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle-formation and liposome-display of protein and peptide antigens resulting in substantial improvements in immune responses.
About EuBiologics: EuBiologics is a South Korean Biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1(C-Plant) and EcML(Monophosphoryl Lipid A) which is adjuvant at Chuncheon Plant 2(V-Plant). The total capacity of the COVID-19 vaccine is currently in the hundreds of millions of doses per year.
About EuBiologics’ EuIMT Technology: EuBioloigcs’ Immune Modulation Technology using genetically engineered Monophosphoryl Lipid A (MLA), called EcML that is a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems including EcML. Eubiologics’ EcML and POP BIO’s SNAP technologies synergize to create ultrapotent next-generation vaccines.
Contact Information:
Jonathan Smyth
President
+13152200087
Original Source:
POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial